About Mosunetuzumab
            
            Class: | Monoclonal antibody; bispecific T-cell engager.
Use: | Treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Adult dose: | Initial dose: 1 mg on Day 1, 2 mg on Day 8, and 60 mg on Day 15 of Cycle 1; 60 mg on Day 1 of Cycle 2; 30 mg on Day 1 of Cycles 3-8. Each cycle is 21 days.
Pediatric dose: | Not established for pediatric use.
Side effects: | Common side effects include cytokine release syndrome, fatigue, rash, pyrexia, and h
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody; bispecific T-cell engager.
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
                 
                
                
                    
                        Storage Requirements
                    
                    Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze.
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: F.Hoffmann - La Roche Ltd[Basel;Switzerland], Switzerland
                    
                    
                    Package Size
                    1 Glass Vial
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 1321.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        Initial dose: 1 mg on Day 1, 2 mg on Day 8, and 60 mg on Day 15 of Cycle 1; 60 mg on Day 1 of Cycle 2; 30 mg on Day 1 of Cycles 3-8. Each cycle is 21 days.
                    
                    
                        Pediatric Dose
                    
                    
                        Not established for pediatric use.
                    
                 
                
                
                    
                        Side Effects
                    
                    Common side effects include cytokine release syndrome, fatigue, rash, pyrexia, and headache.
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Known hypersensitivity to mosunetuzumab or any of its excipients.
         
        
        
            
                Important Warnings
            
            Monitor for cytokine release syndrome, serious infections, and tumor lysis syndrome. Premedicate with corticosteroids, antihistamines, and antipyretics to mitigate infusion-related reactions.
         
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.